Boswellia serrata
The most-studied species in the boswellia genus, with the strongest evidence base built on AKBA-standardized extracts (5-Loxin, AprèsFlex/Aflapin). Active boswellic acids are 5-lipoxygenase inhibitors that reduce leukotriene-driven inflammation. Multiple RCTs and a 2020 meta-analysis support modest pain and function improvements in knee osteoarthritis. Promising signals exist for ulcerative colitis and bronchial asthma but trials are small and old.
Quick decision guide
May help most
Knee osteoarthritis pain and stiffness in adults who prefer a non-NSAID option or want an adjunct alongside NSAIDs. AKBA-enriched extracts (5-Loxin 100–250 mg/day, AprèsFlex 100 mg/day) have the strongest direct evidence.
Common dosing range
100–250 mg/day standardized AKBA-enriched extract (5-Loxin or AprèsFlex). 300–900 mg/day three times daily for older gum-resin formulations.
When to expect effects
5–7 days for AprèsFlex / 5-Loxin 250 mg; 4–6 weeks for full effect with standard extracts.
Watch out for
May increase bleeding risk with warfarin/anticoagulants. GI upset and rare elevations in liver enzymes at high doses.
Evidence snapshot
What is it
Boswellia serrata, also known as Indian frankincense, is a tree native to India, North Africa, and the Middle East whose gum resin has been used in traditional Ayurvedic medicine for thousands of years. Modern supplements use standardized extracts containing boswellic acids, particularly for joint and inflammatory conditions.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Knee osteoarthritis Good Evidence | VAS pain reduction ~8 points; WOMAC pain reduction ~14 points vs placebo; onset within 5–7 days for AKBA-enriched extracts | Adults with mild-to-moderate knee OA who want a non-NSAID option or adjunct | 5–7 days (AprèsFlex / 5-Loxin 250 mg); 4–6 weeks for full effect with standard extracts |
Ulcerative colitis (mild-to-moderate) Limited Evidence | 82% remission vs 75% sulfasalazine in a single small RCT | Adults with mild–moderate UC seeking an adjunct alongside standard therapy | 4–6 weeks |
Bronchial asthma Limited Evidence | 70% improvement vs 27% placebo in a single small RCT | Adults with mild asthma curious about a non-conventional adjunct alongside standard therapy | 4–6 weeks |
Rheumatoid arthritis (adjunct) Limited Evidence | Modest improvement in tender joint count and CRP in small adjunct trials | RA patients on stable DMARDs wanting an adjunct for residual joint pain | 6–12 weeks |
Cerebral edema (radiation-induced, high-dose oncology setting) Limited Evidence | Imaging-based edema reduction at 3,600 mg/day in small trials | Patients in oncology care, prescribed and monitored | Weeks of high-dose supervised use |
Knee osteoarthritis
- Effect
- VAS pain reduction ~8 points; WOMAC pain reduction ~14 points vs placebo; onset within 5–7 days for AKBA-enriched extracts
- Best fit
- Adults with mild-to-moderate knee OA who want a non-NSAID option or adjunct
- Time
- 5–7 days (AprèsFlex / 5-Loxin 250 mg); 4–6 weeks for full effect with standard extracts
Ulcerative colitis (mild-to-moderate)
- Effect
- 82% remission vs 75% sulfasalazine in a single small RCT
- Best fit
- Adults with mild–moderate UC seeking an adjunct alongside standard therapy
- Time
- 4–6 weeks
Bronchial asthma
- Effect
- 70% improvement vs 27% placebo in a single small RCT
- Best fit
- Adults with mild asthma curious about a non-conventional adjunct alongside standard therapy
- Time
- 4–6 weeks
Rheumatoid arthritis (adjunct)
- Effect
- Modest improvement in tender joint count and CRP in small adjunct trials
- Best fit
- RA patients on stable DMARDs wanting an adjunct for residual joint pain
- Time
- 6–12 weeks
Cerebral edema (radiation-induced, high-dose oncology setting)
- Effect
- Imaging-based edema reduction at 3,600 mg/day in small trials
- Best fit
- Patients in oncology care, prescribed and monitored
- Time
- Weeks of high-dose supervised use
Evidence for 5 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Knee osteoarthritis
Supplement benefitBoswellia serrata's strongest evidence is in knee OA. The Sengupta 2008 RCT (n=75, 90 days) tested 5-Loxin (30% AKBA) at 100 or 250 mg/day vs placebo and found significant improvements in pain (VAS) and physical function (WOMAC, Lequesne) at both doses; the 250 mg dose showed faster onset (within 7 days). The Yu 2020 meta-analysis pooled 7 RCTs (545 patients) and reported pooled VAS pain reduction of 8.33 points and WOMAC pain reduction of 14.22 points vs placebo, with consistent stiffness reductions. AprèsFlex (20% AKBA, enhanced absorption) at 100 mg/day shows similar improvements with a lower daily dose. Effects are real but modest; boswellia is not a substitute for surgery in severe OA.
Bottom line: Best-evidenced indication. Choose an AKBA-standardized extract (5-Loxin or AprèsFlex) for the cleanest evidence match.
Ulcerative colitis (mild-to-moderate)
Disease adjunctThe Gupta 1997 RCT (n=20) tested B. serrata gum resin 350 mg three times daily for 6 weeks against sulfasalazine in ulcerative colitis grade II–III. Remission rates were 82% (boswellia) vs 75% (sulfasalazine), and stool, histopathology, and blood markers improved similarly. The trial is small, old, and used an active-control rather than placebo comparator. Mechanism is plausible (5-LOX inhibition reduces leukotriene-driven mucosal inflammation). Promising but not enough to replace standard UC therapy.
Bottom line: Promising but small evidence base. Don't replace mesalamine, steroids, or biologics with boswellia.
Bronchial asthma
Disease adjunctThe Gupta 1998 RCT (n=40) tested B. serrata gum resin 300 mg three times daily for 6 weeks. 70% of treated patients improved (dyspnea, rhonchi, FEV1, FVC, PEFR, eosinophil count) vs 27% of placebo controls. The 5-LOX pathway is mechanistically relevant to asthma (leukotrienes drive bronchoconstriction). Small, old, single-trial evidence. Boswellia is not a substitute for inhaled corticosteroids or rescue bronchodilators in established asthma.
Bottom line: Old, small, single-trial signal. Interesting but don't substitute for inhalers.
Rheumatoid arthritis (adjunct)
Disease adjunctSmaller trials in RA have shown improvements in tender joint counts and CRP when boswellia is added to standard DMARDs, but the effect sizes are smaller than for OA and the trial quality is lower. The 5-LOX mechanism is plausible but RA is primarily TNF/IL-6 driven, which boswellic acids don't directly address. Reasonable adjunct, not a substitute for DMARDs or biologics.
Bottom line: Weaker case than for OA. Useful only as an adjunct alongside DMARDs.
Cerebral edema (radiation-induced, high-dose oncology setting)
Disease adjunctSmall trials in patients with cerebral edema from glioma or radiation therapy showed reductions in edema volume on imaging at 3,600 mg/day boswellia. These are oncology-specialty doses, not consumer doses, and used in supervised settings. Not a self-care indication.
Bottom line: Specialist-only indication. Don't self-treat with 3,600 mg/day boswellia.
How it works
How to take it
What to track
Bottom line: Choose AKBA-standardized extract (5-Loxin 100–250 mg/day or AprèsFlex 100 mg/day) for the cleanest evidence-to-product match. Reassess at 8–12 weeks.
5 commercial forms
Compare the main delivery options and what they’re best suited for.
AprèsFlex / Aflapin (20% AKBA)
Fast-actingPatented Boswellia serrata extract with enhanced AKBA bioavailability. Clinical trials show knee OA improvement at 100 mg/day (single capsule) within 5–7 days. Convenient dose and the lowest daily quantity needed.
Engineered enhanced AKBA absorption; works without fatty meal.
5-Loxin (30% AKBA)
Most studied AKBA extractBoswellia serrata extract enriched to 30% AKBA. The Sengupta 2008 trial established 100–250 mg/day efficacy in knee OA; the 250 mg dose shows fastest onset (within 7 days).
Higher AKBA % than standard 65% boswellic acid extracts; well-absorbed with food.
Standardized B. serrata extract (65–70% boswellic acids)
ConventionalOlder standardization spec — total boswellic acids 65–70% but variable AKBA content. Used in many generic supplement products. Typically dosed 300–500 mg 2–3×/day.
Decent absorption with food; AKBA fraction unclear without spec.
Boswellia serrata phytosome
Enhanced absorptionBoswellic acids complexed with phosphatidylcholine for improved absorption. Several brands market phytosome forms at lower doses (250–500 mg/day). Limited direct head-to-head evidence vs AKBA extracts.
Phytosome technology improves absorption of fat-soluble compounds.
Boswellia gum resin (traditional)
Old-schoolCrushed gum resin in capsules, the original form used in Gupta 1997 (UC) and Gupta 1998 (asthma) trials. Typical dose 300–400 mg three times daily. Less concentrated and less consistent than standardized extracts.
Variable boswellic acid content; older clinical data.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Increased bleeding risk when combined with warfarin or other anticoagulants — discuss with prescriber before adding.
Rare reports of liver enzyme elevation at high chronic doses. Monitor if using >3,000 mg/day for >3 months.
Allergic skin reactions (contact dermatitis) reported with topical use; rare with oral.
Who should avoid it
- People on warfarin, apixaban, rivaroxaban, dabigatran, or other anticoagulants — bleeding risk.
- Pregnant or breastfeeding women — safety data inadequate; traditional use in pregnancy not endorsed by modern guidance.
- People scheduled for surgery — discontinue 2 weeks prior due to bleeding-risk theory.
- Children — safety in pediatric populations not established.
Pregnancy & breastfeeding
Not enough safety data to recommend in pregnancy or breastfeeding. Some traditional uses include emmenagogue (menstruation-promoting) activity, raising theoretical miscarriage concern. Avoid unless a clinician advises otherwise.
Bottom line: Generally well-tolerated for short-to-medium-term use. The most important interaction is with anticoagulants. Stop 2 weeks before any surgery.
Interactions
Boswellic acids may have antiplatelet activity and additive bleeding risk. MSKCC explicitly flags this. Monitor INR closely; consult prescriber before starting.
Boswellia inhibits 5-LOX while NSAIDs inhibit COX — different pathways, often used together intentionally. Theoretical additive GI bleeding risk at high combined doses.
Theoretical additive bleeding risk. Caution at high boswellia doses.
Boswellia has anti-inflammatory immunomodulatory effects; theoretical interaction with immunosuppressive regimens. No documented clinical interactions.
Lab studies suggest boswellic acids inhibit CYP3A4. May affect levels of statins, calcium channel blockers, and others. Clinical significance unclear.
Protocols featuring Boswellia serrata
Evidence-backed routines where Boswellia serrata plays a role.
Systemic Inflammation Support
longevity
Chronic low-grade systemic inflammation (sometimes called "inflammaging") is a unifying mechanism behind cardiovascular disease, type 2 diabetes, neurodegeneration, autoimmune conditions, and accelerated aging. Unlike acute inflammation (which is necessary and beneficial), chronic inflammation drives tissue damage over years. Measurable markers include hsCRP, IL-6, TNF-alpha, fibrinogen, and homocysteine. This stack targets chronic inflammation through complementary mechanisms: curcumin (NF-kB and COX-2 inhibition with the bioavailability problem solved by phytosome forms), omega-3 EPA (shifts eicosanoid production toward less inflammatory series-3), quercetin (mast cell stabilization and NF-kB modulation), and boswellia (5-LOX inhibition through a distinct pathway). This is distinct from Joint Health & Mobility (osteoarthritis-specific) and Daily Calm (stress-driven). For systemic inflammation, the upstream causes — visceral fat, ultra-processed food intake, chronic stress, poor sleep, sedentary lifestyle — matter more than supplements. The stack is a complementary layer.
RA & Joint Autoimmune
autoimmune
Rheumatoid arthritis affects roughly 1.3 million Americans; psoriatic arthritis another 1 million; ankylosing spondylitis around 250,000. Together with the smaller seronegative spondyloarthropathies they form the family of joint-dominant autoimmune diseases — seropositive (RF, anti-CCP) or seronegative — where the immune system attacks synovium, entheses, and cartilage. Untreated, the consequences are joint destruction, deformity, disability, and significant excess cardiovascular and lung morbidity. The modern standard of care is dramatically better than it was 25 years ago: DMARDs (methotrexate first-line, sulfasalazine, leflunomide, hydroxychloroquine), biologics (anti-TNF: adalimumab, etanercept, infliximab; IL-6: tocilizumab, sarilumab; B-cell: rituximab; T-cell co-stim: abatacept), and small-molecule JAK inhibitors (tofacitinib, upadacitinib, baricitinib). The 2021 ACR RA Guideline recommends early aggressive treatment with methotrexate, escalating to biologic or JAK inhibitor if methotrexate is insufficient. This protocol is a COMPLEMENT to — not a substitute for — disease-modifying therapy. The five supplements stacked here target the inflammatory pathways most relevant to joint autoimmunity: omega-3 EPA (eicosanoid shift, the most evidenced supplement in RA), curcumin (NF-kB and COX-2 inhibition, with trial evidence specifically in RA), vitamin D (deficiency strongly linked to disease activity), boswellia (5-LOX inhibition, evidence strongest in osteoarthritis but mechanistically applicable), and ginger (COX/LOX inhibition, modest meta-analytic evidence). Layer this on top of the Autoimmune Foundation protocol for the universal autoimmune baseline. CRITICAL: see a rheumatologist FIRST. Early aggressive treatment with methotrexate (with or without a biologic) is the new standard of care for moderate-to-severe RA. The biologic-era outcomes — remission, no joint damage on imaging, normal function — are dramatically better than the older-generation methotrexate-only outcomes, which themselves were dramatically better than the pre-DMARD era. Do NOT replace methotrexate or a biologic with supplements.
Food sources
| Food | Amount | %DV |
|---|---|---|
| Boswellia serrata (Indian frankincense) | Resin / extract — not a food | — |
Boswellia serrata (Indian frankincense)
- Amount
- Resin / extract — not a food
- %DV
- —
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
What is AKBA?⌄
AKBA (acetyl-11-keto-beta-boswellic acid) is the most potent active compound in Boswellia serrata, particularly active as a 5-LOX inhibitor. Enhanced-AKBA extracts are formulated to contain higher AKBA percentages and may be effective at lower total doses.
How is it different from regular pain relievers?⌄
NSAIDs inhibit cyclooxygenase (COX) enzymes. Boswellia serrata inhibits 5-lipoxygenase (5-LOX), a different inflammation pathway. Effects are typically more modest than NSAIDs but with a better safety profile for long-term use.
When will I see results for joint pain?⌄
Improvements typically develop over 4 to 8 weeks of consistent use. Some users notice subjective benefits earlier; full effects take time.
Can I take Boswellia serrata with turmeric?⌄
Yes. These two botanicals work through different anti-inflammatory pathways and are commonly combined in joint and inflammation formulas. They are well tolerated together.
Is Boswellia serrata safe during pregnancy?⌄
No. Boswellia may stimulate uterine activity and should be avoided during pregnancy.
References by claim
Rheumatoid arthritis (adjunct)
Memorial Sloan Kettering — About Herbs — Boswellia (2024) link
Knee osteoarthritis
Ulcerative colitis (mild-to-moderate)
Gupta et al., 1997 — Eur J Med Res — Boswellia serrata ulcerative colitis (1997) link
Bronchial asthma
Gupta et al., 1998 — Eur J Med Res — Boswellia serrata bronchial asthma (1998) link
Track Boswellia serrata with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.